3月25日 - ** 学岩生物股价SRRK.O盘前上涨3.4
** 该公司称，美国FDA接受了SRRK的药物apitegromab的优先审评，预计将于9月22日做出决定；欧盟药品监管机构也接受了该药物的审评。
** 该公司的药物可治疗脊髓性肌肉萎缩症，这种疾病会阻止神经肌肉发育所需的蛋白质的生成，导致儿童无力行走、说话和吞咽
** 在一项后期研究中，与服用安慰剂的患者相比，服用 apitegromab 的患者运动功能得到了更好的改善。
** 截至上次收盘，SRRK今年迄今已上涨近17
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.